Biotech and Emerging Biopharma (EBP) companies continue to shape global drug development, originating the majority of new medicines and driving innovation globally. In 2024, EBPs accounted for 63% of global clinical trial starts and 85% of U.S. novel drug launches, with growing influence from China, Europe, and beyond.

Join experts from IQVIA Biotech and the IQVIA Institute for Human Data Science for a dynamic panel discussion about how biotech sponsors are evolving their business models and clinical strategies to gain traction in today’s complex environment.

This webinar will explore:

• Global biotech momentum: U.S. and China’s leadership, and shifting trial geographies
• Next-gen R&D: AI, novel modalities and productivity breakthroughs
• Enrollment innovation: Tackling recruitment bottlenecks and boosting early-stage agility
• Global trial strategies: Rise of single-country and patient-centric models

Whether you're advancing your first asset or scaling globally, this session offers actionable insights to navigate the evolving biotech landscape.

Speakers:

Erin Finot, MS, MBA,
Vice President, Immuno-Oncology and Cell & Gene Therapy

Alexander Roland, PhD,
R&D Research Director

For more information and to register, click here.